W
WAVEMAN · COMPANY
KVUE · Kenvue Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

KVUE

Kenvue Inc.
PHARMA & BIOTECH · PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS · CIK 0001944048
CONGRESS · 2☆ WATCH
INSIDER NET · 180D
-$746.8K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
2
FUNDS ADDED · QTR
519
13F, latest reported quarter
REVENUE GROWTH
-2.1%
XBRL, annual
NET MARGIN
9.7%
CONVERSIONS · 180D
7
codes C/M, not in net · $0 priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$746.8K over 180 days
-$67.0K over 90 days
below 58% of Pharma & Biotech
CONGRESS
2 members bought in the last year
more than 65% of Pharma & Biotech
FUNDS
519 funds added or opened last quarter
more than 97% of Pharma & Biotech
REVENUE
-2.1% year over year
below 60% of Pharma & Biotech
MARGIN
9.7% net margin
more than 80% of Pharma & Biotech
BUYBACKS
$197.0M repurchased, FY to 2025-12-28
more than 76% of Pharma & Biotech
SHORT
3.3% of shares outstanding short · 3.4 days to cover · settled 2026-07-31
below 55% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
519 funds added or opened positions in the latest 13F quarter, of 1,013 holders.
2 members of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -5.5%
-5.5%12M
-32%-21%-11%+0%2025-092025-102025-122026-032026-052026-072026-09 2025-12-12 · Smith Jeffrey C bought $55.6M2025-12-11 · Smith Jeffrey C bought $55.4M2026-05-08 · Orlando Matthew sold $679.8K2026-06-10 · Howlett Heather sold $67.0K
INSIDER BUYINSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows a net $746.8K sold by insiders over 180 days, 519 funds added last quarter, 2 Congress member(s) bought in 12 months. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Kenvue Inc. insiders sold a net $746.8K of stock across 7 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Howlett Heather
CFO & CAO
SELL
2026-06-10
3,700.0
$67.0K
Orlando Matthew
General Counsel
SELL
2026-05-08
38,491.3
$679.8K
Smith Jeffrey C
Director
BUY
2025-12-12
3,200,000.0
$55.6M
Smith Jeffrey C
Director
BUY
2025-12-11
3,177,694.0
$55.4M
Lawson Carlton
Group President EMEA & LA
SELL
2025-03-13
17,100.0
$393.8K
7 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 2 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
FMR LLC
157,051,418.0 sh
$3.0B
BlackRock, Inc.
150,825,694.0 sh
$2.9B
VANGUARD CAPITAL MANAGEMENT LLC
125,314,564.0 sh
$2.4B
STATE STREET CORP
121,619,054.0 sh
$2.3B
VANGUARD PORTFOLIO MANAGEMENT LLC
93,303,762.0 sh
$1.8B
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Renaissance IPO ETF
$11.9M POSITION · AS OF 2026-03-31
10.0%
Fidelity SAI Merger Arbitrage Fund
$45.2M POSITION · AS OF 2026-04-30
7.9%
Select Consumer Staples Portfolio
$60.9M POSITION · AS OF 2026-02-28
5.1%
Nuance Concentrated Value Fund
$2.2M POSITION · AS OF 2026-04-30
5.1%
VIP Consumer Staples Portfolio
$10.9M POSITION · AS OF 2026-03-31
4.9%
Independent Franchise Partners US Equity Fund
$62.0M POSITION · AS OF 2026-03-31
4.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122023-05
REVENUE$15.1B$15.5B$15.4B
GROSS PROFIT$8.8B$9.0B$8.6B
OPERATING INCOME$2.4B$1.8B$2.5B
NET INCOME$1.5B$1.0B$1.7B
EPS (DILUTED)0.760.540.90
OPERATING CASH FLOW$2.2B$1.8B$3.2B
CASH$1.1B$1.1B$1.4B$1.2B
LONG-TERM DEBT$7.7B
BUYBACKS$197.0M$235.0M$7.0M
DIVIDENDS PAID$1.6B$1.6B$766.0M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →